GLMD (Galmed Pharmaceuticals) EBITDA Margin %: 0.00% (As of Dec. 2025)


GLMD Galmed Pharmaceuticals Ltd GLMD
27 GF Score
Price $0.59
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals EBITDA Margin %?

Galmed Pharmaceuticals GLMD +2.71% 27 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Galmed Pharmaceuticals ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Galmed Pharmaceuticals's EBITDA for the three months ended in Dec. 2025 was $-3.04 Mil. Galmed Pharmaceuticals's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Galmed Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Galmed Pharmaceuticals  (NAS:GLMD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Galmed Pharmaceuticals EBITDA Margin % Related Terms

Galmed Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals EBITDA Margin % Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Galmed Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLMD vs RNAZ, ARTL, CDT: EBITDA Margin % Comparison

For the Biotechnology subindustry, Galmed Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's EBITDA Margin % falls into.


GLMD
27GF Score
Galmed Pharmaceuticals Ltd GLMD
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Galmed Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.51/0
= %

Galmed Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.042/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Galmed Pharmaceuticals (GLMD) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galmed Pharmaceuticals and its competitors. According to the industry distribution chart, Galmed Pharmaceuticals ranks #999999 out of 945 companies in the Biotechnology industry.
Is Galmed Pharmaceuticals' EBITDA Margin % too high?
Galmed Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Galmed Pharmaceuticals ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' EBITDA Margin % compare to RNAZ and ARTL?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #999999 out of 945 companies for EBITDA Margin %. This places Galmed Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score

Get the complete analysis for GLMD

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price